Drug Trial Radar · NCT04291248
A Study of Anlotinib Combined With AK105 Injection in Subjects With Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Advanced Solid Tumor
Last checked: Nov 19, 2026Latest source record: Mar 2, 2020 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
138
Planned (sponsor's estimate)
Start
Mar 2020
Primary completion
Dec 2022
Study completion Dec 2022
Sponsor
- Lead sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Mar 2, 2020
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is designed to evaluate the efficacy and safety of Anlotinib combined with AK105 injection or AK105 monotherapy in subjects with MSI-H or dMMR advanced solid tumors. In this study, 138 subjects will be enrolled, and those who met the admission criteria will divide into cohort 1 (anlotinib combined with AK105) and cohort 2 (AK105 ). The first phase of this study is a randomized, open-label, parallel-controlled, multicenter design, in which 30 subjects are randomly enrolled in two cohorts. The second phase is to continue enrollment of cohort 1 or cohort 2 when which cohort has the better clinical benefit than the other one.
Conditions
- MSI-H or dMMR Advanced Solid Tumors
Interventions
AK105Drug
AK105 is a humanized monoclonal antibody that specifically binds to PD-1. AK105 has a typical antibody structure and is composed of two lgG1 subtype heavy chains and two kappa subtypes light chains covalently linked by disulfide bonds.
AnlotinibDrug
A multi-target receptor tyrosine kinase inhibitor.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Overall response rate (ORR) assessed by Independent Review Committee (IRC)Time frame: up to 96 weeks
Locations
9 sites in 1 country. Site status is shown where the registry gives one.
Beijing Hospital
Beijing, Beijing Municipality, China
Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College
Beijing, Beijing Municipality, China
Chinese Academy of Medical Sciences, Peking Union Medical College Hospital
Beijing, Beijing Municipality, China
Peking University International Hospital
Beijing, Beijing Municipality, China
The Third Affiliated Hospital of Harbin Medical University
Harbin, Heilongjiang, China
Jiangsu Cancer Hospital
Nanjing, Jiangsu, China
The Second Affiliated Hospital of The PLA Air Force Medical University
Xi’an, Shanxi, China
Shanxi Cancer Hospital
Xi’an, Shanxi, China
Tianjin Cancer Hospital
Tianjin, Tianjin Municipality, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.